09:42 AM EDT, 07/23/2024 (MT Newswires) -- Anixa Biosciences ( ANIX ) said Tuesday that the US Food and Drug Administration has approved its partner Moffitt Cancer Center's individual patient Investigational New Drug application, allowing a second dose of its CAR-T therapy for a patient indicating "clinical activity" to the initial treatment.

The company said the approval follows biopsy results indicating tumor necrosis, inflammation, and T-cell infiltration in the patient at the lowest dose level.

The ongoing phase 1 trial, conducted by Moffitt Cancer Center, is focused on patients with recurrent ovarian cancer who have not responded to standard treatments, Anixa added.

Price: 3.06, Change: -0.07, Percent Change: -2.24